S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NYSE:TAK

Takeda Pharmaceutical News Headlines

$17.44
-0.46 (-2.57 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$17.25
Now: $17.44
$17.51
50-Day Range
$17.83
MA: $18.37
$18.97
52-Week Range
$12.43
Now: $17.44
$20.42
Volume4.13 million shs
Average Volume3.26 million shs
Market Capitalization$54.98 billion
P/E Ratio38.76
Dividend Yield4.13%
Beta0.96

Headlines

Takeda Pharmaceutical (NYSE TAK) News Headlines Today

Source:
SourceHeadline
Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest UpdateTakeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Update
americanbankingnews.com - January 18 at 2:49 AM
Blood Plasma Products Market Worth Observing Growth | Innovative Research, Takeda Pharmaceutical, OctapharmaBlood Plasma Products Market Worth Observing Growth | Innovative Research, Takeda Pharmaceutical, Octapharma
marketwatch.com - January 14 at 8:55 PM
The Stocks That 3 Japan-Centered Gurus Agree OnThe Stocks That 3 Japan-Centered Gurus Agree On
finance.yahoo.com - January 14 at 8:55 PM
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference - MarketWatchTakeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference - MarketWatch
marketwatch.com - January 12 at 2:17 AM
Global Biosimilar Therapeutic Peptides Market Report 2020: Market is Expected to Recover by 2023 as a CAGR of 30.48% - Forecast to 2030Global Biosimilar Therapeutic Peptides Market Report 2020: Market is Expected to Recover by 2023 as a CAGR of 30.48% - Forecast to 2030
benzinga.com - January 11 at 4:16 PM
The Top 7 Pharmaceutical Stocks for the Next 10 YearsThe Top 7 Pharmaceutical Stocks for the Next 10 Years
msn.com - January 11 at 4:16 PM
Takeda to Present at The 39th Annual J.P. Morgan Healthcare ConferenceTakeda to Present at The 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 11 at 11:15 AM
C-MET & HGF Inhibitors Market Analysis 2021: Market Dynamics, Top Players, Type, Applications, Trends, Regional Segmented, Outlook and Forecast 2026C-MET & HGF Inhibitors Market Analysis 2021: Market Dynamics, Top Players, Type, Applications, Trends, Regional Segmented, Outlook and Forecast 2026
marketwatch.com - January 11 at 1:14 AM
3 Low Price-Book Ratio Stock Picks3 Low Price-Book Ratio Stock Picks
finance.yahoo.com - January 10 at 3:13 PM
Subcutaneous Injection Market Analysis By Top Countries Data, Market Size, Revenue, Price, Share, Growth Rate, Forecast to 2026Subcutaneous Injection Market Analysis By Top Countries Data, Market Size, Revenue, Price, Share, Growth Rate, Forecast to 2026
marketwatch.com - January 8 at 4:31 AM
RPT-EXCLUSIVE-As Olympics loom, Japanese approval of Modernas COVID-19 vaccine unlikely till MayRPT-EXCLUSIVE-As Olympics loom, Japanese approval of Moderna's COVID-19 vaccine unlikely till May
reuters.com - January 7 at 11:30 PM
Cancer API Market 2021- COVID 19 Analysis, Explosive Growth Opportunity And Business Challenges in Global Industry Forecast till 2023Cancer API Market 2021- COVID 19 Analysis, Explosive Growth Opportunity And Business Challenges in Global Industry Forecast till 2023
marketwatch.com - January 6 at 10:28 PM
TAK Crosses Below Key Moving Average LevelTAK Crosses Below Key Moving Average Level
nasdaq.com - January 5 at 4:18 PM
Takeda Pharmaceutical Target of Unusually High Options Trading (NYSE:TAK)Takeda Pharmaceutical Target of Unusually High Options Trading (NYSE:TAK)
americanbankingnews.com - January 5 at 7:18 AM
Takeda Completes Sale of Select Non-Core Assets to CheplapharmTakeda Completes Sale of Select Non-Core Assets to Cheplapharm
finance.yahoo.com - January 5 at 6:16 AM
Cancer Biological Therapy Market outlook, Future Scope, Demands and Projected Industry Growths to 2024Cancer Biological Therapy Market outlook, Future Scope, Demands and Projected Industry Growths to 2024
marketwatch.com - January 4 at 12:39 PM
Global Over the Counter Drugs Market, By Product, By Dosage Form, By Distribution Channel, By Region, Forecast & Opportunities, 2025Global Over the Counter Drugs Market, By Product, By Dosage Form, By Distribution Channel, By Region, Forecast & Opportunities, 2025
benzinga.com - January 4 at 7:39 AM
AstraZeneca sells drug rights for $400 millionAstraZeneca sells drug rights for $400 million
marketwatch.com - January 4 at 7:39 AM
Expanded use of Takedas Iclusig OKd by FDAExpanded use of Takeda's Iclusig OK'd by FDA
seekingalpha.com - December 23 at 8:30 PM
CANbridge Pharmaceuticals Appoints General Manager of ChinaCANbridge Pharmaceuticals Appoints General Manager of China
businesswire.com - December 22 at 12:34 PM
Global Pharmaceutical Drugs Market 2020 Industry Challenges, Top Manufacturers, Key Countries with Forecast to 2025Global Pharmaceutical Drugs Market 2020 Industry Challenges, Top Manufacturers, Key Countries with Forecast to 2025
marketwatch.com - December 22 at 7:33 AM
Takeda Pharma Agrees To Sell Select Non-Core Assets To Hasten Biopharma For $322 MlnTakeda Pharma Agrees To Sell Select Non-Core Assets To Hasten Biopharma For $322 Mln
nasdaq.com - December 21 at 9:59 AM
U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CMLU.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML
finance.yahoo.com - December 18 at 6:49 PM
Is TAK A Good Stock To Buy Now?Is TAK A Good Stock To Buy Now?
finance.yahoo.com - December 18 at 12:20 AM
iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform ...iMetabolic Biopharma Corporation Announces Expansion of its Strategic OmniAb Antibody Discovery Partnership with Ligand Pharmaceuticals Accelerating iMetabolic’s iPlatform ...
businesswire.com - December 17 at 2:18 PM
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of ...U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of ...
businesswire.com - December 15 at 11:11 AM
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic EsophagitisU.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
finance.yahoo.com - December 15 at 11:11 AM
Global Pharmaceuticals and Biotechnology R&D Market 2020 Segmentation: Based on Type, Endpoint Interface, Application and Geography to 2025Global Pharmaceuticals and Biotechnology R&D Market 2020 Segmentation: Based on Type, Endpoint Interface, Application and Geography to 2025
marketwatch.com - December 14 at 9:29 AM
KalVista Pharmaceuticals: Caution WarrantedKalVista Pharmaceuticals: Caution Warranted
seekingalpha.com - December 9 at 2:34 PM
Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next DecadeTakeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade
finance.yahoo.com - December 8 at 8:55 PM
Gout Therapeutics Market Anticipated To Expand At A CAGR Around 15.7% During 2019-2027|AstraZeneca plc, Merck & Co. Inc., Regeneron PharmaceuticalsGout Therapeutics Market Anticipated To Expand At A CAGR Around 15.7% During 2019-2027|AstraZeneca plc, Merck & Co. Inc., Regeneron Pharmaceuticals
marketwatch.com - December 8 at 4:36 AM
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary AngioedemaTakeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
finance.yahoo.com - December 8 at 4:36 AM
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding DisordersTakeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
finance.yahoo.com - December 7 at 1:34 PM
Takeda Says Phase 3 SOLSTICE Trial Met Its Primary Endpoint - Quick FactsTakeda Says Phase 3 SOLSTICE Trial Met Its Primary Endpoint - Quick Facts
nasdaq.com - December 4 at 9:06 AM
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary EndpointNew Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
finance.yahoo.com - December 4 at 9:06 AM
Y-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in IsraelY-mAbs and Takeda Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) and Omburtamab in Israel
finance.yahoo.com - December 4 at 9:06 AM
Enthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and DevelopmentEnthera Pharmaceuticals Appoints Kazumi Shiosaki to Its Board of Directors and Lisa Olson to Its Scientific Advisory Board to Push Forward Company Growth and Development
businesswire.com - December 3 at 5:59 PM
At 8.5% CAGR, Marine Pharmaceuticals Market Size Set to Register 47330 million USD by 2026At 8.5% CAGR, Marine Pharmaceuticals Market Size Set to Register 47330 million USD by 2026
marketwatch.com - December 3 at 7:50 AM
Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]Takeda Further Enables Hemophilia A Personalized Care With Launch of myPKFiT® Software for ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]
finance.yahoo.com - December 2 at 4:47 PM
PDE Inhibitors Market Estimated to Soar Higher During 2021 to 2030| Hanmi Science Holding, Boehringer Ingelheim, Takeda PharmaceuticalsPDE Inhibitors Market Estimated to Soar Higher During 2021 to 2030| Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals
marketwatch.com - December 1 at 2:46 AM
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia PacificTakeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
finance.yahoo.com - November 30 at 9:46 PM
Takeda loses bid to narrow pay-for-delay case ahead of trialTakeda loses bid to narrow pay-for-delay case ahead of trial
reuters.com - November 27 at 10:51 PM
Exelixis Says Takeda Receives Approval For Cabometyx In Japan - Quick FactsExelixis Says Takeda Receives Approval For Cabometyx In Japan - Quick Facts
nasdaq.com - November 27 at 5:51 PM
Takeda Pharmas Venkayya on Global Race for Covid VaccinesTakeda Pharma's Venkayya on Global Race for Covid Vaccines
msn.com - November 24 at 5:27 PM
XOMA earns $2M milestone payment from TakedaXOMA earns $2M milestone payment from Takeda
seekingalpha.com - November 16 at 12:14 PM
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary AngioedemaFinal Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
finance.yahoo.com - November 13 at 9:28 AM
Zhongchao soars 46% on contract renewal by TakedaZhongchao soars 46% on contract renewal by Takeda
seekingalpha.com - November 12 at 9:02 AM
Zhongchao Inc. and Takeda Pharmaceutical Expand Scope of Cooperation in ChinaZhongchao Inc. and Takeda Pharmaceutical Expand Scope of Cooperation in China
finance.yahoo.com - November 12 at 9:02 AM
takeda teams up with OrigiMed in innovative medicinestakeda teams up with OrigiMed in innovative medicines
seekingalpha.com - November 11 at 9:34 AM
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative MedicinesOrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines
finance.yahoo.com - November 11 at 9:34 AM
This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.